Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course - PubMed (original) (raw)

. 1995 Jan 1;154(1):450-8.

Affiliations

PMID: 7527821

Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course

M K Racke et al. J Immunol. 1995.

Abstract

Experimental allergic encephalomyelitis (EAE) is an autoimmune disease characterized by central nervous system inflammation and demyelination. Retinoids regulate cell differentiation and growth by binding to and activating retinoic acid receptors, which seem to be nuclear transcription factors. The effect of retinoids on chronic relapsing EAE produced by the transfer of myelin basic protein (MBP)-specific lymph node cells (LNC) was studied. All-trans-retinoic acid (tRA) inhibited the proliferation of MBP-specific LNC in vitro. However, the capacity of these cells to transfer EAE was markedly reduced by concentrations of tRA that only mildly inhibited T cell proliferation. The presence of tRA during in vitro MBP-specific LNC activation resulted in a considerable increase in IL-4 mRNA, whereas mRNA for IL-2, TNF-alpha, and IFN-gamma was decreased. Increased IL-4 also was detected in culture supernatants. However, the presence of a neutralizing Ab to IL-4 (11B11) during MBP-specific LNC activation in vitro did not reverse the inhibition of encephalitogenicity caused by tRA. The administration of retinoids in vivo resulted in an improved clinical course, even when given after disease onset. These findings suggest that T cell activation in the presence of tRA results in the development of T cells of the Th2 phenotype, which, in turn, might be responsible for the decrease in the encephalitogenicity of MBP-specific T cells. The modulation by retinoids of an immune response dominated by Th1-like T cells to one in which the protective cytokines of Th2-like cells predominate may have potential relevance for human demyelinating diseases such as multiple sclerosis.

PubMed Disclaimer

Cited by

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells.
Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK, Lovett-Racke AE. Yang Y, et al. J Exp Med. 2009 Jul 6;206(7):1549-64. doi: 10.1084/jem.20082584. Epub 2009 Jun 22. J Exp Med. 2009. PMID: 19546248 Free PMC article.
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.
Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Golovina TN, et al. PLoS One. 2011 Jan 6;6(1):e15868. doi: 10.1371/journal.pone.0015868. PLoS One. 2011. PMID: 21253593 Free PMC article.
Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.
Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Racke MK, et al. J Clin Invest. 1995 Nov;96(5):2195-203. doi: 10.1172/JCI118274. J Clin Invest. 1995. PMID: 7593605 Free PMC article.
Experimental immunotherapies for multiple sclerosis.
Martin R, McFarland H. Martin R, et al. Springer Semin Immunopathol. 1996;18(1):1-24. doi: 10.1007/BF00792605. Springer Semin Immunopathol. 1996. PMID: 8984675 Free PMC article. Review.
Retinoic acid inhibits CD25+ dendritic cell expansion and γδ T-cell activation in experimental autoimmune uveitis.
Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D. Liang D, et al. Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3493-503. doi: 10.1167/iovs.12-11432. Invest Ophthalmol Vis Sci. 2013. PMID: 23611991 Free PMC article.

Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course - PubMed (original) (raw)